Does metformin cause vitamin B12 malabsorption and deficiency?

Metformin-induced vitamin B12 malabsorption and subsequent deficiency are well-established clinical phenomena. While metformin is the cornerstone of type 2 diabetes management, its long-term use is associated with a progressive decline in serum B12 levels.

Clinical evidence and outcomes

Extensive longitudinal data, including the Diabetes Prevention Program Outcomes Study (DPPOS), demonstrate that metformin use significantly increases the risk of vitamin B12 deficiency.

• Prevalence and Risk: Metformin users have approximately 67% higher odds of deficiency compared to non-users. In randomized controlled trials, metformin increased the absolute risk of B12 deficiency by 7.2 percentage points (p < 0.001) over a 4.3-year period.
• Dose and Duration: The risk is strongly dose- and duration-dependent. Significant clinical impacts typically emerge after 3–5 years of use, with higher daily doses (≥1,500 mg) carrying the greatest risk.
• Clinical Consequences: Chronic deficiency can lead to macrocytic anemia and peripheral neuropathy. Notably, B12 deficiency-related neuropathy can be misdiagnosed as diabetic neuropathy, potentially leading to inappropriate treatment.

Mechanistic explanations

Metformin interferes with vitamin B12 status through a specific physiological mechanism in the digestive tract.

• Calcium Antagonism: Vitamin B12 absorption requires the binding of the intrinsic factor (IF)-B12 complex to the cubilin receptor in the terminal ileum. This process is dependent on divalent calcium cations.
• Receptor Interference: Metformin carries a positive charge that antagonizes the calcium-dependent binding at the ileal cell membrane, effectively "blocking" the receptor and reducing fractional B12 bioavailability by approximately 28% per dose.
• Reversibility: This mechanism is confirmed by the fact that oral calcium supplementation can acutely reverse metformin-induced B12 malabsorption in human tracer studies.

Clinical implications

Given the cumulative nature of this deficiency, healthcare guidelines now prioritize proactive management.

• Monitoring Standards: The American Diabetes Association (ADA) recommends periodic monitoring of vitamin B12 levels in long-term metformin users, particularly those with anemia or peripheral neuropathy.
• Supplementation: Oral B12 supplementation is generally effective at overcoming the malabsorptive effect, as high doses can bypass the receptor-mediated pathway via passive diffusion.

Bottom line

Metformin causes a dose-dependent reduction in vitamin B12 absorption by interfering with calcium-dependent receptors in the ileum. This leads to a progressive decline in B12 stores over several years, making regular screening essential for long-term users to prevent neurological and hematological complications.